International Stem Cell Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ISCO research report →
Price Chart
About the company
International Stem Cell Corporation (ISCO) is a clinical-stage biotechnology firm dedicated to creating therapeutic and biomedical solutions for a global market, spanning North America, Asia, Europe, and beyond. Central to its offerings are products derived from its proprietary human parthenogenetic stem cells, a unique form of pluripotent stem cells. ISCO is actively engaged in developing specialized cell types, such as neural stem cells, which hold promise for treating Parkinson's disease and other disorders affecting the central nervous system.
- CEO
- Andrey Semechkin
- IPO
- 2007
- Employees
- 33
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on ISCO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.24M
- P/E
- -4.46
- PEG
- 0.02
- P/S
- 0.24
- P/B
- 31.13
- EV/EBITDA
- -28.44
- Div Yield
- 0.00%
- Gross Margin
- 54.85%
- Op Margin
- -3.50%
- Net Margin
- -6.12%
- ROE
- 19.43%
- ROIC
- -9.44%
Latest fiscal year · YoY change
- Revenue
- $9.10M+0.2%
- Gross Profit
- $5.07M-4.8%
- Op Income
- $-267,000
- Net Income
- $-418,000-100.0%
- EPS
- $-0.05-91.6%
- OCF Growth
- -38.5%
- FCF Growth
- +77.1%
- 52W High
- $0.54
- 52W Low
- $0.12
- 50D MA
- $0.36
- 200D MA
- $0.21
- Beta
- -0.05
- RSI (14)
- 39
- Avg Volume
- 29.13K
No earnings-call transcripts are available for ISCO yet.
- Free Float
- 46.2%
- Shares Outstanding
- 8.00M
- Float Shares
- 3.70M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 16, 26 | MAIER PAUL V | sell | 30,000 |
| Sep 11, 26 | MAIER PAUL V | sell | 32,802 |
| Jun 11, 26 | Don Wright | other | 182,584 |
| Jun 11, 26 | Don Wright | other | 30,000 |
| Jun 11, 26 | MAIER PAUL V | other | 182,584 |
| Jun 11, 26 | MAIER PAUL V | other | 30,000 |
| Jun 17, 25 | Don Wright | other | 532,786 |
| Jun 17, 25 | Don Wright | other | 30,000 |
| Jun 17, 25 | MAIER PAUL V | other | 532,786 |
| Jun 17, 25 | MAIER PAUL V | other | 30,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ISCO coverage
Recent articles, reports, and earnings notes.
No research on ISCO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ISCO report →International Stem Cell (OTCMKTS:ISCO) Shares Cross Above 200 Day Moving Average – What’s Next?
defenseworld.net · Mar 28
International Stem Cell (OTCMKTS:ISCO) Shares Cross Above Two Hundred Day Moving Average – Should You Sell?
defenseworld.net · Mar 10
International Stem Cell Corp. (OTCMKTS:ISCO) Sees Large Increase in Short Interest
defenseworld.net · Feb 12
International Stem Cell Corp. (OTCMKTS:ISCO) Sees Large Increase in Short Interest
defenseworld.net · Feb 12
Short Interest in International Stem Cell Corp. (OTCMKTS:ISCO) Grows By 21.9%
defenseworld.net · Feb 5
International Stem Cell (OTCMKTS:ISCO) Share Price Crosses Above 200 Day Moving Average – What’s Next?
defenseworld.net · Jan 21
International Stem Cell (OTCMKTS:ISCO) Stock Passes Above 200-Day Moving Average – Should You Sell?
defenseworld.net · Dec 12
International Stem Cell Corporation Announces 2024 Fourth Quarter and Year-End Results
accessnewswire.com · Mar 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.